Company intelligence / Profile preview

Aptah Bio

San Carlos, California, United Statesaptah-bio.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Aptah Bio is developing a new class of RNA-based therapies that modulate the transcription machinery by targeting U1-snRNP to restore regular gene expression. Their lead compound APT20TTMG has shown recovery of homeostatic protein expression and positive biological effects in cell and animal models. All programs are currently at preclinical stage.

Therapeutic areas: OncologyImmunologyRare DiseasesOphthalmologyNeurology
Modalities: RNA-based small moleculesChemical drugs
Industry: Biotech

Drug pipeline

4 assets

APT20TTMG

Preclinical

3 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Aptah Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aptah Bio.

Explore the full profile